Hit-to-lead studies on benzimidazole inhibitors of ITK: discovery of a novel class of kinase inhibitors

Bioorg Med Chem Lett. 2007 Jul 1;17(13):3660-5. doi: 10.1016/j.bmcl.2007.04.045. Epub 2007 Apr 25.

Abstract

Benzimidazole 1 was identified as a selective inhibitor of ITK by high throughput screening. Hit-to-lead studies defined the SAR at all three substituents. Reversing the amide linkage at C6 led to 16, with a fivefold improvement of potency. This enhancement is rationalized by the conformational preference of the substituent. A model for the binding of the benzimidazoles to the ATP-binding site of ITK is proposed.

MeSH terms

  • Adenosine Triphosphate / chemistry
  • Benzimidazoles / chemical synthesis
  • Benzimidazoles / chemistry*
  • Binding Sites
  • Chemistry, Pharmaceutical / methods*
  • Drug Evaluation, Preclinical / methods
  • Enzyme Inhibitors / pharmacology
  • Humans
  • Hydrogen Bonding
  • Inhibitory Concentration 50
  • Models, Chemical
  • Protein Binding
  • Protein Kinase Inhibitors / chemical synthesis*
  • Protein Kinase Inhibitors / chemistry
  • Protein-Tyrosine Kinases / antagonists & inhibitors*
  • Structure-Activity Relationship

Substances

  • Benzimidazoles
  • Enzyme Inhibitors
  • Protein Kinase Inhibitors
  • Adenosine Triphosphate
  • Protein-Tyrosine Kinases
  • emt protein-tyrosine kinase